Literature DB >> 11138722

Role of cannabinoid receptor in the brain as it relates to drug reward.

T Yamamoto1, K Takada.   

Abstract

Understanding of cannabinoid (CB) actions has been remarkably advanced during the last decade, due mainly to the identification of the G-protein-coupled cannabinoid receptors, namely, CB1 receptors that are predominantly found in the brain and CB2 receptors that are exclusively found in peripheral tissues. Endogenous ligands for these receptors have also been identified. Research to date suggests that the analgesic effect of cannabinoids and the enhancement of opioid analgesia by cannabinoids are both CB1 receptor-mediated via the activation of opioid receptors. The involvement of the CB1 receptor in mediating reinforcing and physical dependence-producing effects of opioids has also been suggested, with the former being considered the result of interaction with the dopaminergic neurotransmission in the midbrain dopamine system. However, the discriminative stimulus effects of cannabinoids have been reported to be highly specific in that the effects were not substituted by other classes of compounds including opioidergic and dopaminergic agents nor were they antagonized by antagonists of various neurotransmission systems, suggesting that the discriminative stimulus effects only involve the cannabinoid system. Thus the cannabinoid actions appear to be classifiable into at least two kinds: 1) those mediated directly through cannabinoid receptors and 2) those mediated indirectly through other systems such as opioidergic systems. Detailed research into these actions may help to elucidate not only the mechanisms of action of exogenous cannabinoids but also the role of endogenous cannabinoids, especially in the brain reward system.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11138722     DOI: 10.1254/jjp.84.229

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  10 in total

1.  The GNB3 C825T polymorphism and depression among subjects with alcohol dependence.

Authors:  A P Prestes; F Z C Marques; M H Hutz; C H D Bau
Journal:  J Neural Transm (Vienna)       Date:  2006-08-08       Impact factor: 3.575

Review 2.  Cannabis cue-elicited craving and the reward neurocircuitry.

Authors:  Francesca M Filbey; Samuel J DeWitt
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-11-09       Impact factor: 5.067

3.  A Study of the Impact of Cannabis on Doses of Discharge Antipsychotic Medication in Individuals with Schizophrenia or Schizoaffective Disorder.

Authors:  Taiwo Babatope; Jigar Chotalia; Rania Elkhatib; Satyajit Mohite; Joel Shah; Sumana Goddu; Ruchir Arvind Patel; Osarhiemen Ruth Aimienwanu; Devanshu Patel; Titilayo Makanjuola; Olaoluwa O Okusaga
Journal:  Psychiatr Q       Date:  2016-12

Review 4.  Role of Cannabinoid CB2 Receptor in Alcohol Use Disorders: From Animal to Human Studies.

Authors:  María Salud García-Gutiérrez; Francisco Navarrete; Ani Gasparyan; Daniela Navarro; Álvaro Morcuende; Teresa Femenía; Jorge Manzanares
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

5.  Effects of cannabinoid CB1 receptor antagonist rimonabant in consolidation and reconsolidation of methamphetamine reward memory in mice.

Authors:  Lu-lu Yu; Xue-yi Wang; Mei Zhao; Yu Liu; Yan-qin Li; Fang-qiong Li; Xiaoyi Wang; Yan-xue Xue; Lin Lu
Journal:  Psychopharmacology (Berl)       Date:  2009-01-16       Impact factor: 4.530

6.  A cannabinoid CB(1) receptor antagonist ameliorates impairment of recognition memory on withdrawal from MDMA (Ecstasy).

Authors:  Yoko Nawata; Takato Hiranita; Tsuneyuki Yamamoto
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

7.  Early cannabis use and DSM-IV nicotine dependence: a twin study.

Authors:  Arpana Agrawal; Michael T Lynskey; Michele L Pergadia; Kathleen K Bucholz; Andrew C Heath; Nicholas G Martin; Pamela A F Madden
Journal:  Addiction       Date:  2008-11       Impact factor: 6.526

8.  Association Study of Two Cannabinoid Receptor Genes, CNR1 and CNR2, with Methamphetamine Dependence.

Authors:  Y Okahisa; M Kodama; M Takaki; T Inada; N Uchimura; M Yamada; N Iwata; M Iyo; I Sora; N Ozaki; H Ujike
Journal:  Curr Neuropharmacol       Date:  2011-03       Impact factor: 7.363

Review 9.  Emerging Evidence for Cannabis' Role in Opioid Use Disorder.

Authors:  Beth Wiese; Adrianne R Wilson-Poe
Journal:  Cannabis Cannabinoid Res       Date:  2018-09-01

10.  Inhibition of Monoacylglycerol Lipase Reduces the Reinstatement of Methamphetamine-Seeking and Anxiety-Like Behaviors in Methamphetamine Self-Administered Rats.

Authors:  Yoko Nawata; Taku Yamaguchi; Ryo Fukumori; Tsuneyuki Yamamoto
Journal:  Int J Neuropsychopharmacol       Date:  2019-02-01       Impact factor: 5.176

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.